Free Trial
NASDAQ:AEON

AEON Biopharma 3/29/2024 Earnings Report

AEON Biopharma logo
$0.41 0.00 (-0.73%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$0.40 0.00 (-0.49%)
As of 09:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AEON Biopharma EPS Results

Actual EPS
-$51.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

AEON Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

AEON Biopharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

AEON Biopharma's next earnings date is estimated for Tuesday, May 13, 2025, based on past reporting schedules.

Conference Call Resources

Remove Ads

AEON Biopharma Earnings Headlines

AEON Biopharma (NASDAQ:AEON) Shares Up 2.5% - What's Next?
The Crypto Market is About to Change Lives
I've discovered something so significant about the 2025 crypto market that I had to put everything else aside and write a book about it. This isn't just another Bitcoin prediction – it's a complete roadmap for what I believe will be the biggest wealth-building opportunity of this decade. The evidence is so compelling, I'm doing something that probably seems insane: I'm giving away my entire book for free.
AEON Biopharma Announces CEO Transition
See More AEON Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AEON Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AEON Biopharma and other key companies, straight to your email.

About AEON Biopharma

AEON Biopharma (NASDAQ:AEON), a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

View AEON Biopharma Profile

More Earnings Resources from MarketBeat